其实已有两种提取物被使用和正在临床试验中:
1. Sativex®,用于缓解癌症病人疼痛,正在第三期临床试验中.
2. Epidiolex® ,用于治疗Dravet综合征（婴儿严重肌阵挛性癫痫）.
For example, in April 2014, GW Pharmaceuticals announced that FDA granted Fast-Track designation20 to its investigational drug product Sativex®, composed primarily of two cannabinoids: CBD (cannabidiol) and THC, administered as a metered-dose oromucosal spray, for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication. In addition, on June 6, 2014, GW Pharmaceuticals announced that FDA granted Fast-Track designation to its investigational CBD product, Epidiolex®, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.21
FDA---Mixed Signals: The Administration’s Policy on Marijuana—Part Four—the Health Effects and Science
American Cancer Society这一篇长文也可以参考:
Marijuana - American Cancer Society
